Abstract:BACKGROUND:Cholangiocarcinoma (CCA), consisting of intrahepatic (IHCCA), perihilar (PHCCA), and distal (DCCA) CCA, is a type of highly aggressive malignancy with a very dismal prognosis. Potential biomarkers and drug targets of CCA are urgently needed. As a new member of the Annexin (ANXA) family, the role of ANXA10 in the progression and prognosis of CCA is unknown.METHODS:Potential PHCCA biomarkers were screened by transcriptome sequencing of 5 pairs of PHCCA and adjacent tissues. The clinical significance of ANXA10 was evaluated by analyzing its correlation with clinicopathological variables, and the prognostic value of ANXA10 was evaluated with univariate and multivariate analyses. The function of ANXA10 in the epithelial-mesenchymal transition (EMT), proliferation, invasion and metastasis was detected with in vitro and in vivo experiments. Moreover, we screened the key molecule in ANXA10-induced CCA progression by mRNA sequencing and evaluated the correlation between PLA2G4A and ANXA10. The effect of PLA2G4A downstream signaling, including Cyclooxygenase 2, Prostaglandin E2(PGE2) and Signal transducer and activator of transcription 3(STAT3), on EMT and metastasis was further detected with in vitro and in vivo experiments.FINDINGS:ANXA10 expression was upregulated in PHCCA and DCCA but not in IHCCA. High ANXA10 expression was significantly associated with poor tumor differentiation and prognosis. ANXA10 promoted the proliferation, migration and invasion of the PHCCA cells. PLA2G4A expression was regulated by ANXA10 and high PLA2G4A predicted poor prognosis in PHCCA and DCCA. ANXA10 facilitated EMT and promoted metastasis by upregulating PLA2G4A expression, thus increasing PGE2 levels and activating STAT3.INTERPRETATION:ANXA10 was an independent prognostic biomarker of PHCCA and DCCA but not IHCCA. ANXA10 promoted the progression of PHCCA and facilitated metastasis by promoting the EMT process via the PLA2G4A/PGE2/STAT3 pathway. ANXA10, PLA2G4A and their downstream molecules, such as COX2 and PGE2, may be promising drug targets of PHCCA and DCCA.

Annexin10 Promotes Extrahepatic Cholangiocarcinoma Metastasis by Facilitating EMT Via PLA2G4A/PGE2/STAT3 Pathway

Annexin A5 regulates hepatocarcinoma malignancy via CRKI/II-DOCK180-RAC1 integrin and MEK-ERK pathways

Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway

Phospholipase A2 enzymes PLA2G2A and PLA2G12B as potential diagnostic and prognostic biomarkers in cholangiocarcinoma

ANXA1 enhances tumor proliferation and migration by regulating epithelial-mesenchymal transition and IL-6/JAK2/STAT3 pathway in papillary thyroid carcinoma

Overexpressions of Ck2 Beta and Xiap Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

Annexin-1 Downregulation is Associated with Clinical Outcome in Chinese Patients with Hilar Cholangiocarcinoma

Overexpressions of CK2β and XIAP Are Associated with Poor Prognosis of Patients with Cholangiocarcinoma

Relationship of annexin A10 with matrix metalloproteinases-9,vascular endothelial growth factor expressed in human hepatocellular carcinoma and their relationship with clinicopathological features

Annexin A4 and cancer

14-3-3Ζ and Apkc-Ι Synergistically Facilitate Epithelial-Mesenchymal Transition of Cholangiocarcinoma Via GSK-3β/snail Signaling Pathway

Targeting of Annexin A1 in Tumor-Associated Macrophages As a Therapeutic Strategy for Hepatocellular Carcinoma

Anxa5 mediates the in vitro malignant behaviours of murine hepatocarcinoma Hca-F cells with high lymph node metastasis potential preferentially via ERK2/p-ERK2/c-Jun/p-c-Jun(Ser73) and E-cadherin

Annexin A9 promotes cell proliferation by regulating the Wnt signaling pathway in colorectal cancer

PLAU contributes to the development of cholangiocarcinoma via activating NF‐κB signaling pathway

Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis

A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression

Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway

ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway

ANXA2 enhances the progression of hepatocellular carcinoma via remodeling the cell motility associated structures

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements